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forme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond
to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase
(MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known
to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been
developed for use in experiments designed to define the mechanism of TMZ resistance and
the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive
TMZ resistant GBM cells have not been systemically compared. This article reviews the char-
acteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell
lines. It also summarizes potential treatment options for TMZ resistant GBMs.
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Temozolomide (TMZ) is an imidazotetrazine derivative of
the alkylating agent dacarbazine and a prodrug of the anti-
cancer drug Temodar.1 The chemical name of TMZ is 3-
methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide (Fig. 1). TMZ is stable at a pH less than 5 but
at a pH greater than 7 it is rapidly hydrolyzed to 5-(3-
methyltriazen-1-yl) imidazole-4-carboxamide (MTIC).2 The
lipophilic nature of TMZ permits it to penetrate the blood-
brain-barrier (BBB) allowing it to be administered orally.Use of Temozolomide (sold as Temodar) to
treat brain tumors
TMZ is active against human cancers such as melanomas and
astrocytomas.3e6 It was approved by the US Food and Drug
Administration (FDA) for use in the treatment of refractory
anaplastic astrocytoma in adults in 1999 and newly diagnosed
adult glioblastoma (GBM) patients in 2005. The antitumor
effect of TMZ is schedule-dependent with multiple adminis-
trations being more effective than a single treatment. In a
Phase I clinical trial, the recommended dose of TMZ was
750e1000mg/m2givenorally for 5daysperweek for4weeks.7
Temodar capsules containing 5e250 mg of TMZ are available
for its oral administration to patients and in vials containing
100 mg for those being given TMZ intravenously.
Concomitant therapy using both Temodar and radiation
improved overall survival of newly diagnosed adult GBM
patients relative to those treated with radiation aloneN3-methylade
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Fig. 1 Mechanism of Temozolomide and Temozolomide resistanc
guanine and the N3 on adenine by the addition of methyl groups. The
repair (MMR),beremovedbybaseexcisionrepair (BER)by theactionof
or deakylated by the action of a demethylating enzyme such as O6-m
when MMR is expressed and active. When MGMT, APNG, and BER prot(12.1 / 14.6 months median survival).8 Newly diagnosed
GBM patients tend to be given 75 mg/m2/day of Temodar
for 6 weeks concomitantly with focal radiotherapy (60 Gy)
followed by 6 cycles of in which they are given 150 mg/m2
once daily for 5 days in a row followed by 23 days of no
treatment prior to the next cycle. Patients given Temodar
iv are injected over a 90 min time period with the same
amount that is administered orally.
Mechanism of action of Temozolomide
TMZ is a DNA alkylating agent known to induce cell cycle
arrest at G2/M and to eventually lead to apoptosis.9 At
physiologic pH it is converted to the short-lived active
compound, MTIC. MTIC is further hydrolyzed to 5-amino-
imidazole-4-carboxamide (AIC) and to methylhydrazine.
The cytotoxicity of TMZ is mediated by its addition of
methyl groups at N7 and O6 sites on guanines and the O3 site
on adenines in genomic DNA (Fig. 1). Alkylation of the O6
site on guanine leads to the insertion of a thymine instead
of a cytosine opposite the methylguanine during subse-
quent DNA replication, and this can result in cell death.
Temozolomide resistance in natural TMZ
resistant GBM cell lines
To identify TMZ resistant GBM cell lines, we conducted
literature searches in PubMed/MEDLINE using the terms
Temozolomide/TMZ resistant glioblastoma/GBM and ac-
quired Temozolomide/TMZ resistant glioblastoma/GBM.nine
nine
nine
Cell death 
(TMZ sensitive)
G), Base excision repair (BER), 
nine-DNA methyltransferase (MGMT)
MT/APNG/BER
MZ resistant)
R
MGMT/APNG/BER
MMR
e. Temozolomide (TMZ) modifies DNA or RNA at N7 and O6 sites on
methylated sites can remain mutated, be fixed by DNA mismatch
aDNAglycosylase suchas, alkylpurine-DNA-N-glycosylase (APNG),
ethylguanine methyltransferase (MGMT). Cells are TMZ sensitive
eins are expressed, GBM cells are resistant to TMZ.
Table 1 Characteristics of intrinsic (pre-existing) TMZ resistant GBM and high grade glioma cell lines.
TMZ
sensitive
cellsa
TMZ resistant
cellsb
IC50 (mM) to TMZ Molecular events
of TMZ resistant cells
TMZ resistant
cells are sensitive to
References
U87
U373
U87: 172 mM
U373: 131 mM
Baer JC et al.10
SWB61 SWB77 SWB61: 30 mM
SWB77: 350 mM
No clear correlation
between MGMT activity
and response to TMZ
Loss of the p53-inducible
cell cycle checkpoint is
most effective
mechanism for TMZ
resistance, but p53
mutation status itself
cannot determine the
resistance of tumors to
TMZ
Bocangel DB
et al.11
U373 T98G U373: <10 mM
T98G: >1000 mM
T98G cells are sensitive
to the combination of
TMZ and AGT inhibitor
O6-benzylguanine (BG)
than TMZ treatment
alone
Kanzawa T
et al.12
U87,
U373
T98G U87: 100 mM
U373: 100 mM
T98G: >500 mM
TMZ suppressed
telomerase activity in
U87 and U373 cells, but
not in T98G cells
AGT inhibitor O6-
benzylguanine (BG)
sensitized T98G cells to
TMZ and also suppressed
telomerase activity
Kanzawa T
et al.13
AO2
U251
SKMG1
T98G
U251nu/nu
AO2, U251: <20 mM
SKMG1: <40 mM
T98G: >1000 mM
U251nu/nu: >1000 mM
T98G and U251nu/nu
cells express high level
of MGMT
IFN-b (100 IU/ml)
sensitizes T98G and
U251nu/nu cells to TMZ
(100 mM) via down-
regulates MGMT
expression and
activation of p53
pathway
Natsume A
et al.14
CD133
negative
primary
cultured
cells
CD133 positive
primary
cultured cells
CD133 positive primary
cultured cells are
resistant to TMZ
compared to CD133
negative primary
cultured cells
established from GBM
patients. The resistance
is due to higher level of
BCRP1, MGMT, and
apoptosis inhibition
genes mRNA expression
Liu G et al.15
LNT-229,
U87
LN-18, T98G e
both cells have
mutant p53
U87: 7 mM
LN-18: 511 mM
T98G: 502 mM
LN-18 and T98G cells had
high levels of MGMT
activity
TMZ resistant cells are
sensitive to MGMT
inhibitor O6-BG (50 mM)
and restores p53
function by p53 rescue
agent CP-31398, but not
sensitive to PARP
inhibitors 3-
aminobenzamide (1 mM)
Hermisson M
et al.16
200 S.Y. Lee
Table 1 (continued )
TMZ
sensitive
cellsa
TMZ resistant
cellsb
IC50 (mM) to TMZ Molecular events
of TMZ resistant cells
TMZ resistant
cells are sensitive to
References
and NU1025 (200 mM)
U87 T98G U87: 204 mM
T98G: 1585 mM
T98G cells express high
level of MGMT (wild type
promoter), but U87 cells
express low level of
MGMT (due to partial
methylation of the
promoter)
Combination of oncolytic
adenovirus D-24-RGD
and TMZ improved the
survival of T98G cells via
decrease MGMT mRNA
Alonso MM
et al.9
A172,
U251
Combination of tumor
necrosis factor-related
apoptosis-inducing
ligand (TRAIL) (30 ng/ml)
and TMZ (100 mM)
sensitize A172, U251,
and U87 cells, but not
effective to TMZ
resistant cells
Uzzaman M
et al.17
U251 T98G Combination of IFN-b/
TMZ had significant
synergistic antitumor
effect on the growth of
both T98G and U251
subcutaneous tumors,
because IFN-b
inactivates MGMT via p53
gene induction and
enhances the
therapeutic efficacy to
TMZ
Natsume A
et al.18
U87, U251,
M059K,
M059J
U251: 50 mM Ujifuku K
et al.19
AMC 3046,
Gli6,
Hs 683,
U251, VU-
98, VU-109,
VU-122
T98G, VU-28,
VU-110
U251: <50 mM
T98G: >500 mM
All TMZ-resistant GBM
cells express MGMT
protein whereas no
MGMT protein could be
detected in TMZ-
sensitive GBM cells
van Nifterik KA
et al.20
T98G T98G cells have
overexpression of MGMT,
BER (base excision
repair), NAMPT
(nicotinamide
phosphoribosyl
transferase), and NADþ
Combination of
NADþ biosynthesis
inhibition with BER
inhibition decreased
T98G cell survival
Goellner EM
et al.21
SW1088, U87,
U251
CCF-STTG1,
LN-18, T98G,
U343-MG
CCF-STTG1 cells do not
express MGMT protein,
but express p16INK4A
LN-18 and T98G cells
express MGMT protein
Lee SY et al.22
A172 T98G A172: <100 mM
U251: <250 mM
T98G: >250 mM
NHA: >250 mM
TMZ resistance is the
result of APNG and MGMT
activity
A172: MGMT/APNG null
U251: MGMT null, APNG
high
Agnihotri S
et al.23
(continued on next page)
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TMZ
sensitive
cellsa
TMZ resistant
cellsb
IC50 (mM) to TMZ Molecular events
of TMZ resistant cells
TMZ resistant
cells are sensitive to
References
T98G: MGMT/APNG high
U87, U251 T98G, U138 U87: <500 mM
U251: <500 mM
T98G: >500 mM
U138: >500 mM
T98G and U138 cells
express MGMT protein
TMZ (50 mg/kg) alone did
not decrease the growth
of T98G xenograft tumor
Combination of Valproic
acid (VPA) and TMZ,
because of via reduced
MGMT expression
Combination of VPA
(300 mg/kg) and TMZ
(50 mg/kg) decreased
T98G tumor growth
Ryu CH et al.24
LNT-229,
LN-308
LN-18 Upregulation of MGMT Happold C
et al.25
KMG4, LN235,
LN308,
U87
T98G, U138,
LN382
MGMT expression Kohsaka S
et al.26
U87 T98G Significant increase in
the miR-9 levels in TMZ
treated GBM cells
Munoz JL
et al.27
U87 T98G TMZ treated GBM cells
have activated
EGFR/ Activated JNK-
ERK1/2-AP-1
axis/ Increased
connexin 43 (Cx43)
Munoz JL
et al.28
A172, LN71,
LN405,
U373
LN229 St-Coeur P-D
et al.29
U87 T98G U87: 10 mM
T98G: 600 mM
T98G cells express MGMT
but p53 deficient. U87
cells lack MGMT but p53
proficient
APE1, an essential base
excision repair pathway
enzyme, knockdown
associated with TMZ
treatment efficiently
reduced cell
proliferation and
clonogenic survival of
resistant cells
Montaldi AP
et al.30
AGT: O6-methylguanine-DNA alkyltransferase; APNG: alkylpurine-DNA-N-glycosylase; APE1: apurinic/apyrimidine endonuclease/redox
factor-1; BCRP1: Breast cancer resistance protein 1; MGMT: O6-methylguanine-DNA methyltransferase; NHA: Normal human astrocytes;
O6-BG: O6-benzylguanine; TMZ: Temozolomide; VPA: Valproic acid.
a Bold indicates TMZ sensitive cell lines which reported at least in two papers.
b Bold indicates TMZ resistant cell lines which reported at least in two papers.
202 S.Y. LeeThe searches indicated that several cell lines have been
identified as TMZ sensitive or TMZ resistant (Table 1).9e30
Well-known TMZ sensitive GBM cells are A172, U87, U251,
and U373. In contrast, the following GBM cells were reported
consistently to be TMZ resistant: LN-18, T98G, and U138. We
reported that CCF-STTG1 andU343-MGGBM cells are also TMZ
resistant.22 The LC50s (50% cell death concentration) pub-
lished for TMZ on TMZ sensitive GBM cells vary. For example,
Hermissonet al.16 andMontaldi etal.30 reported that theLC50s
of TMZ on U87 GBM cells were 7 mM and 10 mM, while Baer
et al.10 and Ryu et al.24 noted it as 172 mMand<500 mM. Those
reported for the lethality of TMZ on U251 GBM cells also var-
ied:<20 mM,14 50 mM,19<250 mM,23<500 mM.24 The variations
in LC50 may reflect the use of different experimental pro-
cedures and cytotoxicity assays (e.g., MTS assay, clonogenicassay). LC50s reported for TMZ on TMZ resistant GBM cells
also varied. For TMZ on T98G GBM cells LC50s were found to
range from >250 mM23 to 1585 mM.9 The U251 derived U251
nu/nu human glioma cells, which have remarkable trans-
plantability to the nude mouse, behaved analogously to the
T98G cells when exposed to TMZ.14 Interestingly, the trend
of the cytotoxic effects of TMZ, as indicated by the LC50s,
indicates that LC50s for TMZ susceptible cells such as U87 or
U251 are lower than those for TMZ resistant ones such as
T98G.9,13,14,16,20,23,24,30 In primary cultured cells, estab-
lished from GBM patients, CD133 positive cells are more
resistant to TMZ than CD133 negative cells.15 While studying
the effects of TMZ on normal human astrocytes (NHA)
Agnihotri et al.23 found that the LC50 was similar to that for
T98G cells (LC50: >250 mM) that are not sensitive to TMZ. In
TMZ resistance in GBM 203another report,31 immortalized normal human astrocytes
which are the most common cell type to cause gliomas had
a TMZ LC50 of 500 mM which is similar to that for TMZ
resistant GBM cells. Our recent unpublished finding that TMZ
is not cytotoxic to NHA as well as TMZ resistant GBM cells
such as T98G and CCF-STTG1 agrees with their results.Molecular events in natural Temozolomide
resistant GBM cells
TMZ is an alkylating agent that acts by methylating DNA
adenine and guanine residues (w90%) to form N3-methyl-
adenine and N7-methylguanine, respectively, and to a
lesser extent (5e10%) O6-methylguanine (Fig. 1). The
methylated DNA can be repaired by base excision or DNA
mismatch repair pathways. While O6-methylguanine meth-
yltransferase (MGMT) acts to reverse methylation of the O6
position of guanine, Bocangel et al.11 found no correlation
between MGMT activity and response to TMZ in their study
of 7 human glial tumor cell lines. Their results indicated
that a non-functional p53 response to DNA damage was
associated more with TMZ resistance than was MGMT ac-
tivity. They also suggested that p53 mutation status is not
the only factor to determine the resistance of cancer cells
to TMZ. However, in other studies natural TMZ resistant
GBM cells were found to express higher levels of MGMT
protein than TMZ sensitive GBM cells.9,14e16,20e26,30
Expression of MGMT protein was found to correlate
inversely with the status of MGMT promoter methylation32
although MGMT methylated GBM cells such as T98G cells
can express MGMT protein and show TMZ resistance. Based
on MGMT protein and the MGMT methylated promoter re-
sults different labs hypothesized that the response of GBM
cells to TMZ might be best predicted by 1) their expression
of the MGMT protein,20 and 2) MGMT promoter methylation
status.32 Agnihotri et al. suggested that the TMZ resistance
of T98G GBM cells is due not only to expression of the
MGMT protein but to that of alkylpurine-DNA-N-glycosylase
(APNG) protein as well.23 APNG is a base excision repair
enzyme that functions in the repair of N3-methyladenine
and N7-methylguanine. A higher expression of nuclear
APNG protein correlated with patients having poorer
overall survival compared to patients lacking APNG
expression.23 Some TMZ resistant GBM cells do not express
the MGMT protein. For example, CCF-STTG1 cells do not
express MGMT protein and are resistant to TMZ.22 Instead
of MGMT expression, the CCF-STTG1 cells express more
p16INK4A than TMZ sensitive or other TMZ resistant GBM
cells.22
The impact of MGMT promoter methylation on MGMT
protein expression has been extensively studied in human
GBM patients as well. In studies of GBM patients, MGMT
promoter methylation was found to correlate with
improved survival when they were treated with alkylating
agents like TMZ.33,34 The finding that not all GBM patients
that had MGMT promoter methylation responded to alky-
lating agents indicates, in agreement with results described
above for the cell studies, that there are multiple mole-
cules involved in TMZ resistance.
In addition to MGMT and APNG protein expression, other
proteins and factors have been studied for their effect onTMZ resistance. For example, TMZ resistance is associated
with increased breast cancer resistance protein 1 (BCRP1),
base excision repair (BER), nicotinamide phosphoribosyl
transferase (NAMPT), NADþ, CD133 expression, and inhi-
bition of apoptosis.15,21 Moreover, treatment of U87 and
T98G cells with TMZ (200 mM) for 72 h resulted in increased
miR-9,27 and increased expression of connexin 43 induced
through activation of the epidermal growth factor receptor
(EGFR) and Jun N-terminal kinase-Extracellular Signal
Regulated Kinases 1 and 2-activator protein 1 (JNK-ERK1/
2-AP-1) axis.28 All of these data indicate that TMZ resis-
tance results from a complex cellular response by the GBM
cells.Gene mutations in natural Temozolomide
resistant GBM cells
Possible association between a gene mutation and TMZ
resistance in GBM has not been interrogated systemically.
Although the best studied gene mutation associated with
resistance to TMZ is p53, the results have been mixed.11,35
For example, Blough et al. reported that while expression
of wild type p53 conveyed more resistance to TMZ than
non-functional mutated p53 in cells of established GBM cell
lines, it did not in brain tumor initiating cells.35 In contrast
to those results, TMZ sensitive GBM cells (e.g., A172, U87)
express wild type of p53 and p53 gene mutations were
found in TMZ resistant GBM cells (e.g., LN-18, T98G, U138)
as well as TMZ sensitive GBM cells (e.g., U251, U373).36,37
Therefore, a mutation in the p53 gene does not appear to
be a primary indicator of resistance to TMZ. Interestingly,
we observed that all but one (LN-18) of the TMZ resistant
GBM cells we have studied have a mutation in the HFE
gene22 which functions in iron homeostasis. Mutations in
the HFE gene lead to iron overload in cells expressing it
compared to those expressing wild type HFE. There are two
major mutations (H63D, C282Y) of the HFE gene. TMZ
resistant GBM cells found to express H63D HFE were T98G,
U138, and U343, while the only TMZ resistant GBM cells that
expressed C282Y HFE were CCF-STTG1. It is unknown
whether increased iron or expression of a HFE gene mutant
mediates molecular events associated with TMZ resistance.
In a recent study of tumor tissues from GBM patients,
Nguyen et al. reported that novel MSH6 (mutS homolog 6)
mutations influenced the sensitivity of brain tumor initi-
ating cell lines to TMZ regardless of MGMT promoter
methylation status.38Temozolomide resistance in adapted
Temozolomide resistant GBM cell lines
Adapted TMZ resistant GBM cells have been generated from
both established GBM cell lines and cells isolated from
primary tumors treated with TMZ for different times
(72 he6 months) (Table 2).19,25,26,29,39e48 Cells from known
TMZ sensitive GBM cell lines (e.g., A172, SNB-19, U87, U251,
and U373) have been frequently used to generate adapted
TMZ resistant GBM cells. In studies, known TMZ resistant
GBM cell lines (e.g., LN-18, T98G) were also used.25,44 TMZ
resistant cells have been generated by treating them in a
Table 2 Characteristics of acquired TMZ resistant GBM cell lines.
Host cellsa TMZ resistant cells IC50 (mM) to TMZ Molecular events of adapted TMZ
resistant cells
TMZ resistant cells
are sensitive to
References
Selection method Maintenance method
SF188 Stepwise exposure of the
cells to TMZ (50e300 mM)
for 6 months
Maintain the TMZ
resistant cells in TMZ
free cell culture
medium, but the cells
were frequently
incubated with 300 mM
TMZ
SF188: 426 mM
SF188_R: 1854 mM
Increased activity of AGT
Reduced expression of pro-apoptotic
proteins (Bad, Bax, Bcl-Xs)
No change for mismatch repair
enzymes
Not affected by p53 status, because
parent and TMZ resistant cells contain
mutant p53
TMZ resistant cells
are sensitive to the
AGT inhibitor O6-
benzylguanine (BG)
Ma J et al.39
Primary tumor Incremental
concentrations of TMZ
(2.5, 5, 7.5, 10 mM) for
1 h for 5 consecutive
days. This step was
repeated several times
until the resulting cell
population was resistant
The TMZ resistant cells
re-treated with 10 mM
TMZ every 8-10 passages
Overexpressed MGMT,
Decreased expression of TNFAIP3 (NF-
kB pathway modulator, encode the
zinc finger protein A20), NFKBIA (NF-
kB inhibiting IkB family member),
C8orf4, and LIF
Bredel M et al.40
SNB-19 Incremental
concentrations of TMZ
(3, 5, 10, 20, 30, 60,
150 mM)
Maintain the TMZ
resistant cells in TMZ
free cell culture medium
SNB-19: 1.03 mM
SNB-19A4: 101 mM
SNB-19C1: 55 mM
No detectable MGMT expression in
TMZ resistant cells
Gene alteration (loss of 2p16.1-
2p25.3, loss of partial amplification of
the 4p14.4-4q21.22, loss of
amplification of the 16q12.1e16q22.1
and 1p13.2-1q21.1)
Auger N et al.41
U87, U251,
M059K,
M059J
100 mM TMZ for 2 weeks U251: w50 mM
U251_R: >300 mM
MGMT expression is not involved in
the acquisition of TMZ resistance in
U251_R cells
Up-regulated microRNA such as miR-
10a, miR-195, miR-455-3p
miR-195 knockdown
showed moderate
growth inhibition to
U251_R cells
combined treatment
with both miR-10a or
miR-455-3p inhibitors
with TMZ showed
better cytotoxicity
Ujifuku K et al.19
SNB19, U373 Stepwise increment TMZ
concentrations (1, 2, 5,
10, 20, 50, 100 mM) for 6
months
Maintain the TMZ
resistant cells in 100 mM
TMZ
SNB19: 36 mM
U373: 68 mM
SNB19_R: 280 mM
U373_R: 289 mM
SNB19_R & U373_R cells acquired TMZ
resistance via distinct mechanisms.
SNB19_R: down-regulation of MSH6
message and protein (under
continued presence of TMZ), up-
regulation of BER gene NTL1
U373_R: MGMT expression, but its
expression requires the selective
pressure of continued TMZ presence
Zhang J et al.42
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U251 Stepwise 2 fold increase
of TMZ concentration
from 2.5 mM to 1 mM for 6
months
Maintain the TMZ
resistant cells in 160 mM
TMZ. For over 50
passages, the resistance
to TMZ was retained
Decreased MGMT expression
Decreased mitochondrial DNA copy
number
Large heteroplasmic mtDNA deletions
Remodeling of the entire electron
transport chain (Significant decreases
of complexes I and V and increases of
complexes II/III and IV)
Oliva CR et al.43
U251,
U373,
T98G
TMZ concentration is 2
fold increased every two
passages from 12.5 mM to
800 mM for 2 months
U251: 100 mM
U373: 50 mM
U251_R: 1000 mM
U373_R: 800 mM
TMZ resistant cells do not have
altered MGMT expression, but have
upregulation of STAT3 and pSTAT3
(Ser727) while pSTAT3 (Tyr705) was
decreased
STAT3 siRNA sensitize
TMZ resistant cells
Lee E-S et al.44
LN-18, LNT-
229, LN-308
24 h TMZ exposure every
2 weeks. Increasing
concentration of TMZ for
6 months
LN-308: <40 mM
LN-18: w400 mM
LN-308_R:
>400 mM
LN-18_R: w800 mM
LN-18_R: up-regulation of MGMT
LNT-229_R: down-regulation of DNA
mismatch-repair protein
LN-308_R: reduced methylation of
LINE-1 repetitive elements
Happold C et al.25
U87 Culture the cells for 3
weeks with a low dose of
TMZ
U87: <40 mM
(growth inhibition)
or <10 mM
(clonogenic assay)
U87_R: 150 mM
(growth inhibition)
or >400 mM
(clonogenic assay)
Upregulation of MGMT and STAT3 STAT3 inhibitor Kohsaka S et al.26
U343 Culture the cells with
200 mM of TMZ for 1
month. Continuous TMZ
(150 mM) treatment for
at least 5 months.
U343: <50 mM
U343_R: 280.63 mM
Increased invasiveness
Increased JNK signaling pathway
Activation of known JNK effector
paxillin
JNK inhibitor
SP600125 or JNK
siRNA suppressed up-
regulation of
invasiveness
Ueno H et al.45
U373 At every two passages,
TMZ concentration is
increased subsequently
from 12.5 mM to 500 mM
for months
TMZ resistant cells have upregulation
of glucose, citrate, and isocitrate
levels
TMZ sensitive cells have upregulation
of alanine, choline, creatine, and
phosphorylcholine
A glucose analog (2-
Deoxy-D-glucose)
alone or with TMZ is
cytotoxic to TMZ
resistant cells
St-Coeur P-D
et al.29
U251 Stepwise 2 fold increase
of TMZ concentration
from 1.25 mM to 160 mM
for 10 months
U251: 58 mM
U251_R: 271 mM
Upregulation of MGMT and
phosphorylated-p65
IkBa inhibitor BAY 11-
7082 sensitize TMZ
resistant cells growth
Combination effect of
IkBa inhibitor and
TMZ on TMZ resistant
cells
Wang X et al.46
(continued on next page)
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Table 2 (continued )
Host cellsa TMZ resistant cells IC50 (mM) to TMZ Molecular events of adapted TMZ
resistant cells
TMZ resistant cells
are sensitive to
References
Selection method Maintenance method
A172,
LN229,
U87
Culture the cells with
20 mM of TMZ/ Culture
the survival cells with
40 mM of TMZ/ Culture
the survival cells with
40 mM of TMZ
TMZ resistance is not due to increased
repair of O6-methylguanin but is
correlated to decreased mismatch
repair (MMR) activity such as MSH2
and MSH6
McFaline-Figueroa
JL et al.47
A172,
GBM cancer
stem cells
Culture the cells with
continuous TMZ (200 or
400 mM) for 30 days
GBM3: 98 mM
GBM3_R:
>1000 mM
GBM5: 634 mM
GBM5_R: 1115 mM
TMZ resistant cells grow slowly
Increased histone lysine demethylase
(KDMs) gene expression, especially
KDM5A
No change in MGMT and drug efflux
mechanisms
TMZ resistant cells
are sensitive to the
histone deacetylase
(HDAC) inhibitor
(SAHA 1 mM) and TMZ
(200 mM) combination
treatment
Banelli B et al.48
AGT: O6-methylguanine-DNA alkyltransferase; C8orf4: Chromosome 8 open reading frame 4; HDAC: histone deacetylase; KDM: Histone lysine demethylase; LIF: Leukemia inhibitory factor;
MGMT: O6-methylguanine-DNA methyltransferase; MMR: Mismatch repair; O6-BG: O6-benzylguanine; SAHA: N-hydroxy-N0-phenyl-octanediamide; STAT3: Signal transducers and activators
of transcription 3; TNFAIP3: Tumor necrosis factor-a-induced protein 3.
a Bold indicates that these cell lines were commonly used as host cells to generate acquired TMZ resistant cells.
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TMZ resistance in GBM 207step-wise manner with different concentrations
(1e1000 mM) of TMZ for various time periods (up to 6
months). Identified acquired TMZ resistant GBM cells were
then maintained in medium containing the maximum
treated concentration of TMZ or without TMZ.
Resistance to TMZ of the adapted GBM cells was 2e98
times greater than that of the host cells. Different com-
parisons of the response to TMZ as measured by the TMZ
LC50s of adaptive TMZ resistant GBM cells and host cells
gave variable results. For example, Auger et al.41 reported
that the LC50 obtained for TMZ when it was used to treat
TMZ-resistant SNB-19 cells was 55e101 mM, while in a study
by Zhang et al.42 it was 280 mM. This difference may reflect
the fact that the original responses of the host cells to TMZ
differed in the two laboratories: 1.03 mM vs 36 mM. U87 and
U251 GBM cells have also been commonly used to generate
adaptive TMZ resistant ones. Kohsaka et al.26 found that
the LC50 for TMZ on acquired TMZ resistant U87 cells, iso-
lated after 3 weeks of exposure to low doses of TMZ, was
increased 4 fold, from 40 mM to 150 mM, when measured
using a growth inhibition assay, but by 40 fold, from 10 mM
to 400 mM, using a clonogenic assay. Similarly, Ujifuku
et al.19 found that the LC50 for the effect of TMZ on ac-
quired TMZ resistant U251 cells, isolated after a 2 weeks
exposure to TMZ, increased at least 6 fold from 50 mM to
>300 mM. Some adaptive TMZ resistant GBM cells were
generated using known TMZ resistant cell lines such as LN-
18. After adaptation by exposure to TMZ for 6 months, the
LC50 of TMZ on adapted resistant LN-18 cells increased 2
fold to w800 mM.25Mechanisms of Temozolomide resistance in
adapted TMZ resistant GBM cells
Adaptive TMZ resistant GBM cells differ from their parent
cells at the molecular level. Of particular interest in regard
to TMZ resistance are alterations related to known TMZ
resistance molecules such as MGMT and DNA repair.
Increased MGMT protein expressions were observed in
adaptive TMZ resistant SF188, LN-18, U87, U251, and pri-
mary tumor derived GBM cells.25,26,39,40,46 In addition to an
increased expression of MGMT in adaptive TMZ resistant
GBM cells, they have been reported to show a decrease in
the nuclear factor-Kappa B (NF-kB) pathway modulator
Tumor Necrosis Factor-Alpha-Induced Protein 3 (TNFAIP3)
and up-regulation of p-p65.40,46 Increased expression of
Signal Transducer and Activator of Transcription 3 (STAT3) is
also found in adaptive TMZ resistant U87 cells.26
Analyses of MGMT protein expression in adaptive TMZ
resistant SNB-19, LNT-229, U251, U343 and U373 cells
indicated no change or a decrease in MGMT protein
expression.19,41e44 In adaptive TMZ resistant GBM cells that
did not over-express MGMT, expression of other molecules
found to participate in TMZ resistance were observed. For
example, adaptive TMZ resistant SNB-19 cells showed a loss
of gene amplification41 or down-regulation of MSH6 and up-
regulation of BER gene NTL1.42 Down-regulation of DNA
mismatch-repair protein was also found in adaptive TMZ
resistant LNT-229 cells.25 The adaptive TMZ resistant
U251 cells had an up-regulation of microRNA,19 up-
regulation of STAT3/p-STAT3,42 decreased mitochondrialDNA copy number and remodeling of the mitochondria
electron transport chain.43 Adaptive TMZ resistant GBM
cells also have been reported to show activation of JNK,45
up-regulation of metabolisms of glucose, citrate, and iso-
citrate,29 and an increase in histone demethylase KDM5A
gene expression.48
Temozolomide resistance in animal models
Not many studies have been done to generate TMZ resistant
xenograft animal models (Table 3).43,49e51 These tumors
can be generated by successive injections of TMZ into the
flanks of animals bearing TMZ sensitive GBM cell xenografts.
When the flank tumors are not inhibited by administration
of 120 mg/kg/day of TMZ for 5 days, the tumors are clas-
sified as TMZ resistant. The TMZ resistant xenografts had
higher mitochondrial complex IIeIV activities and
decreased mitochondrial complex I/V activity.43,49 Similar
molecular events were observed in in vitro studies of
adaptive TMZ resistant U251 cells.43 Like some of the
adaptive TMZ resistant GBM cells, strongly induced and
prolonged MGMT protein expression was found in TMZ
resistant xenografts.51
Treatment for Temozolomide resistant GBM
Intrinsic TMZ resistant GBM cells are not treated with just a
single agent but with different drug combinations. The
most widely used single drugs for naturally TMZ resistant
GBM cells are a MGMT inhibitor or a drug to decrease ac-
tivity/inhibit expression of MGMT since the level of MGMT
protein expression is closely related to TMZ resistance.
Treatment with the MGMT inhibitor O6-benzylguanine (O6-
BG) sensitizes TMZ resistant LN-18 and T98G cells to
TMZ.12,16 Interferon-b (IFN-b) also sensitizes TMZ resistant
T98G and U251nu/nu cells via down-regulation of MGMT
expression.14 IFNs are a family of cytokines that have
immunomodulatory, cell differentiation, antiangiogenic,
and antiproliferative effects. The effect of IFN-b on TMZ
resistant GBM cells may be due to its anti-tumor activity
(e.g., cytostatic effects, antitumor immune response).
Treatment with IFN-b also activates the p53 pathway that
can sensitize TMZ resistant GBM cells to TMZ. Treatment of
TMZ resistant tumors with a combination of TMZ and either
O6-benzylguanine or IFN-b was shown to make the cells
more vulnerable to TMZ and synergistic anti-tumor effects
than treatment with TMZ alone.12,18 The effectiveness of
using an oncolytic adenovirus or valproic acid in combina-
tion with TMZ has also been studied.9,24 Knockdown of an
essential base excision repair pathway enzyme apurinic/
apyrimidine endonuclease/redox factor-1 (APE1) also
sensitized TMZ resistant T98G cells to TMZ.30
There are only a few studies of the effects of different
drug combinations lacking TMZ on TMZ resistant GBM cells.
Results of one such study in which an inhibitor of NADþ
biosynthesis was used in combination with a BER inhibitor
indicated that the combination could inhibit TMZ resistant
GBM cells.21 Recent report showed that the combined
treatment of monoclonal antibody against EGFR (Nimotu-
zumab) and mammalian target of rapamycin (mTOR) in-
hibitor (rapamycin) was more cytotoxic than single
Table 3 Characteristics of intrinsic or acquired TMZ resistant xenograft animal models.
Host cell TMZ resistant cells Molecular events of TMZ
resistant GBM xenograft
TMZ resistant cells
are sensitive to
References
Selection method Maintenance
method
GBM Xenograft
lines
Subjecting mice
with established
flank tumors to
successively
higher doses of
TMZ until tumor
growth was no
longer inhibited by
120 mg/kg/day
TMZ for 5 days
By serial passage
of subcutaneous
tumor in mice
Higher complex IIeIV
activities and decreased
activities of complex I/V
Giannini C et al.49
Oliva CR et al.43
TMZ sensitive GBM
Xenograft lines
(GBM12,
GBM22, GBM39)
Subjecting mice
with established
flank tumors to
successively
higher doses of
TMZ until tumor
growth was no
longer inhibited by
TMZ 120 mg/kg/
day for 5 days
By serial passage
of subcutaneous
tumor in mice
Combination of
PARP inhibitor and
TMZ is effective to
primary GBM lines
that have not been
previously
exposed to TMZ
Clarke MJ et al.50
GBM Xenograft
lines
GBM43, GBM44
xenograft lines
Direct
implantation of
patient samples
and subsequent
serial
subcutaneous
propagation in
nude mic
TMZ treatment induce
robust and prolonged
induction of MGMT
expression
Kitange GJ et al.51
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Like intrinsically TMZ resistant GBM cells, acquired TMZ
resistant GBM cells are also vulnerable to O6-benzylgua-
nine.39 Studies of a combination of TMZ and other targeted
drugs on acquired TMZ resistant GBM cells indicated that
the miR-455-3p inhibitor and TMZ were more cytotoxic than
TMZ alone on acquired TMZ resistant U251 cells.19 The
combination of an IkBa inhibitor and TMZ also decreased
their survival.46 Acquired TMZ resistant GBM cells derived
from GBM cancer stem cells, were sensitive to treatment
with a combination of the histone deacetylase (HDAC) in-
hibitor (SAHA 1 mM) and TMZ (200 mM).48 Other drugs
analyzed for their effects on acquired TMZ resistant GBM
cells are inhibition of microRNA-195,19 an inhibitor of STAT3
or STAT3 knockdown,26,44 an inhibitor of JNK or JNK
siRNA,45 and a glucose analog.29 In an animal study, a
combination of TMZ and a poly ADP ribose polymerase
(PARP) inhibitor was found to extend survival of the GBM
orthotopic xenografts.50
In addition to the in vitro and in vivo xenograft studies,
the effectiveness of combination treatments comprised of
TMZ and a pharmacologic agent (e.g., O6-benzylguanine) on
TMZ resistant GBM has been studied in clinical trials. In a
phase I clinical trial, patients with recurrent GBM showed a
marginal response when treated with a combination of TMZanddendritic cell vaccination.52 In aphase II clinical trial, the
combination of TMZ and O6-BG was ineffective on TMZ
resistant GBM patients, but was found to restore TMZ sensi-
tivity in TMZ resistant anaplastic glioma patients.53 The
combination of imatinib and hydroxyurea did not improve
recurrent GBM patient survival in phase III clinical study.54Conclusions
TMZ resistance is a major problem in the treatment of
malignant brain tumors. Studies of numerous intrinsic and
acquired TMZ resistant GBM cells indicate that TMZ resis-
tance is associated with the expression levels of DNA
alkylating proteins and DNA repair enzymes. Results ob-
tained from studies of intrinsic and acquired TMZ resistant
GBM cells support the conclusion that TMZ resistance is not
mediated by a single molecular event but by multiple ones.
Therefore, identification of GBM patients based on the
patient’s gene/protein profiling data could be beneficial for
selecting drugs for their treatment. A potential problem
with the use of TMZ to treat GBM patients is that their tu-
mors may acquire TMZ resistance through alteration not
only in their expression of DNA alkylating proteins and DNA
repair enzymes but in cell signaling pathways as well. While
TMZ resistance in GBM has been primarily studied in vitro
TMZ resistance in GBM 209using different cell models, more studies of TMZ resistance
need to be done using patient derived GBM xenograft ani-
mal models or tumor tissues of TMZ resistant patients in
order to better interrogate potential targets and thera-
peutic options to pursue for human study.
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